Thrombosis and coagulopathy in COVID‐19: An illustrated review
Marcel Levi, Beverley J. Hunt
Abstract
This illustrated review discusses the haemostatic changes seen in patients with severe coronavirus disease 2019 (COVID-19) infection and their possible causes. We discuss the crosstalk between inflammation and coagulation resulting in high levels of acute-phase proteins, very high levels of D-dimers, and absence of disseminated intravascular coagulation seen in patients with severe COVID-19. There appear to be high rates of venous thromboembolism and also, what has been poorly described before in acute lung injury, a high rate of pulmonary immunothrombosis (thrombosis secondary to inflammation).
Topics & Concepts
CoagulopathyMedicineCoronavirus disease 2019 (COVID-19)ThrombosisInflammationDisseminated intravascular coagulationCoronavirusVenous thrombosisIntensive care medicinePulmonary embolismCoagulation2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseImmunologyInternal medicinePathologyInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesVenous Thromboembolism Diagnosis and ManagementCOVID-19 and healthcare impacts